RE:Facts for why KLY will be a massive success. MrBrazilSP wrote: This is a long one but worth the read if you are invested in KLY.
Facts are not the opinions and delusions of a Chicken Little screaming that the sky is falling. Ignore the troll completely and block him. Remember to report abuse on his posts as well. Multiple accounts, excessive bashing, profanity, bullying, etc. I don’t understand his fascination with contention. Until he learns to behave like an adult and be able to hold a mature conversation, I am refusing to acknowledge his posts at all. He really needs to get off of his computer. It depresses me how much time he invests on this board only to argue and spread negativity. 24 hours a day, 7 days a week... My god, he really doesn’t have anything else to do. This board is his life and that is very sad. He has created numerous accounts to dominate the board and talks as if they are other people to keep his posts active. No one else will give him the time of day anymore. Most have flat out blocked him. Don’t feed the troll guys. If you don’t think the stock will grow, then sell and be done with it. Simple.
Here are the actual facts.
1. Phase 2 of their lead product development program evaluating cannabidiol for the prevention of acute graft versus host disease has been extremely positive and encouraging. No patients in the first cohort developed grades 3 or 4 acute GVHD while receiving oral CBD treatment, and only one patient developed grade 2 acute GVHD.
2. Phase 2 will likely be completed in August to early September. Once completed, they are planning a seamless and immediate transition into phase 3 (the final phase).
3. Phase 3 is expected to take roughly 1.5 - 2 years. Not sure where chicken little pulled the 2.5 to 3 year theory from. His phantom phone call to Rob is a complete fabrication. The troll has zero insider information.
4. Current interest from numerous pharma companies to licence the GVHD drug. The business strategy Kaly is pursuing for their GVHD products is to out-license the commercial rights for these products once they have completed the Phase 2 study in prevention of GVHD. They have engaged Echelon Wealth Partners to determine the value, on a risk-adjusted basis, of its CBD therapeutic products for the prevention and treatment of graft versus host disease, and to assist with the review of potential out-licensing opportunities for the commercial rights to these products.
5. Kaly has invented a novel first-in-class cannabinoid molecule for treatment of acute and chronic pain, designated KAL-1816. The progress of this drug is extremely positive and the commercial opportunity is very large.
6. Numerous patents on both drugs. Proprietary rights my friends.
7. The Board of Directors does in fact own stock in the company. The stock options have an exercise price of $0.05 per common share and expire ten years from the date of grant. One third of the options granted will vest on June 19, 2020 and the remaining options will vest in twenty-four equal monthly instalments commencing July 2020.Stock options to purchase 68,698 common shares of Kalytera were granted to Ron Erickson, stock options to purchase 254,345 common shares were granted to Jeff Paley, and stock options to purchase 1,000,000 common shares were granted to Rob Hutchison, who very recently joined the Company's board of directors. In addition, stock options to purchase 11,095,907 common shares of Kalytera were issued to Robert Farrell.
8. Rob Farrell did not give himself a raise. That would be illegal. His increase in salary was voted on by shareholders and the Board of Directors.
9. Kaly is acquiring a 51% stake in a state-of-the-art Clean Bi Design CBD extraction business. This will be amongst the largest such operations in the U.S. This transaction will provide near-term path to revenues. Closing is expected to occur on or about October 1, 2019. They expect to report initial revenues from CBD isolate sales by Q4 2019.
10. Kalytera’s new Consumer Products Division is also planning to launch an E-Commerce website that will support online sales of consumer CBD products derived from hemp, including CBD oils and other CBD consumer products. The platform will support Kalytera’s own family of brands, selling CBD wellness products to all legal CBD markets across the U.S.
11. Completion of Food Effect and QTc Study. Preliminary results for the Food Effect and QTc Study are positive and as expected. CBD was well tolerated, there were no safety concerns and the EKG data that is required to evaluate the effects of CBD on cardiac rhythm have been obtained.
This will give everyone more insight into the operations and future of Kalytera. As you can see, numerous milestones have been reached in what is still the infancy of this company. Kaly is expanding and diversifying its operations as part of its ongoing development and strategy. The ride may be rough my friends but if you have the heart and the patience, you will be part of something great. Again, ignore the fear mongering ramblings of Chicken Little. The sky is not falling. The clouds are clearing and the great vastness of the world is opening. Of course, do your own research and make your own decisions. But ask yourself, “Whom am I going to believe? A company with amazing results thus far, and a management team having combined experience of over 100 years; or the ramblings of a conspiracy nut who sits on his computer 24/7 trolling a stock market chat room?” Best of luck to everyone (even Chicken Little) and happy trading my friends.
Wonderful information - thank you. The only thoughts I have are regarding the current cohort. I believe as of June 25 they expected to complete enrollment for the second cohort in July and it’s an 105-day course of treatment, so they might not be done until sometime in October.